Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

The obesity treatment market is becoming increasingly ... What potential does Amgen's oncology pipeline hold for future growth? Amgen's oncology pipeline, particularly products like AMG 193 ...

BT: Are there other drugs in Eli Lilly’s pipeline targeting obesity or related conditions that we can expect in the near future? VG: India is an important market for Lilly. We are committed to ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions, today announced the ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.